

10823 809

8'24  
31hr 13  
1st. corr. 1318

A-735C

- 1 -

Express Mail No. EV351338396US

828  
1624

**SUBSTITUTED ARYLAMINE DERIVATIVES AND METHODS OF USE**

This application is a continuation of U.S. Patent Application 10/197,960 filed July 17, 2002 which is a continuation-in-part of U.S. Patent Application 10/046,526 filed January 10, 2002 claiming the benefit of U.S. Provisional Application Nos. 60/261,360, filed January 12, 2001, and 60/323,686 filed September 19, 2001, which are hereby incorporated by reference.

10

**FIELD OF THE INVENTION**

This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer and angiogenesis-related disorders.

**BACKGROUND OF THE INVENTION**

Protein kinases represent a large family of proteins which play a central role in the regulation of a wide variety of cellular processes, maintaining control over cellular function. A partial list of such kinases includes abl, Akt, bcr-abl, Blk, Brk, Btk, c-kit, c-met, c-src, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, cRaf1, CSF1R, CSK, EGFR, ErbB2, ErbB3, ErbB4, Erk, Fak, fes, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, flt-1, Fps, Frk, Fyn, Hck, IGF-1R, INS-R, Jak, KDR, Lck, Lyn, MEK, p38, PDGFR, PIK, PKC, PYK2, ros, tie, tie2, TRK, Yes, and Zap70. Inhibition of such kinases has become an important therapeutic target.

Certain diseases are known to be associated with deregulated angiogenesis, for example ocular neovascularisation, such as retinopathies (including diabetic retinopathy), age-related macular degeneration, psoriasis, hemangioblastoma, hemangioma, arteriosclerosis,